Duality Biologics - About the company
Duality Biologics is a public company based in Pudong (China), founded in 2020. It operates as a Developer of ADC therapeutics to treat cancer and autoimmune diseases. Duality Biologics has raised $120M in funding from investors like WuXi Biologics, 6 Dimensions Capital and LAV Asset Management. The company has 3607 active competitors, including 1204 funded and 815 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.
Company Details
Developer of ADC therapeutics to treat cancer and autoimmune diseases. It offers DITAC (Duality Immune Toxin Antibody Conjugate) for solid tumors and DIMAC (Duality Immune Modulating Antibody Conjugate) for auto-immune disorders.
- Website
- www.dualitybiologics.com
- Email ID
- *****@dualitybiologics.com
Key Metrics
Founded Year
2020
Location
Pudong, China
Stage
Public
Total Funding
$120M in 2 rounds
Latest Funding Round
Investors
Ranked
222nd among 3607 active competitors
Employee Count
63 as on Aug 31, 2026
Similar Companies
Exit Details
Public
Duality Biologics's IPO details
Duality Biologics got listed on Apr 15, 2025.
Click here to take a look at Duality Biologics's IPO in detail
Sign up to download Duality Biologics' company profile
Duality Biologics's funding and investors
Duality Biologics has raised a total funding of $120M over 2 rounds. Its latest funding round was a Series B round on May 20, 2021 for $*****. 5 investors participated in its latest round. Duality Biologics has 7 institutional investors.
Here is the list of recent funding rounds of Duality Biologics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 20, 2021 | 6897036 | Series B | 5812691 | 7204274 | 5157437 | 5299567 |
Access funding benchmarks and valuations. Sign up today!View details of Duality Biologics's funding rounds and investors
Duality Biologics' founders and board of directors
Founder? Claim ProfileDuality Biologics' employee count trend
Duality Biologics has 63 employees as of Aug 26. Here is Duality Biologics's employee count trend over the years:
Uncover Duality Biologics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Duality Biologics's Competitors and alternates
Top competitors of Duality Biologics include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Duality Biologics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
5th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
6th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
7th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
8th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
9th |  Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 71/100 | |
10th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 71/100 | |
222nd |  Duality Biologics 2020, Pudong (China), Public | Developer of ADC therapeutics to treat cancer and autoimmune diseases | $120M | 59/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Duality Biologics's competitors? Click here to see the top ones
Duality Biologics's Investments and acquisitions
Duality Biologics has made no investments or acquisitions yet.
Reports related to Duality Biologics
Here is the latest report on Duality Biologics's sector:
News related to Duality Biologics
Filter this listMedia has covered Duality Biologics for a total of 4 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
DualityBio and Genentech Enter Global Collaboration for Next-Generation ADCsPR Newswire•Aug 28, 2026•Genentech, Duality Biologics
•
Ever-Genics "A+H" Accelerates, Plans to Raise 675 Million for Clinical Stage III ADC DrugsSina•Jun 11, 2026•Duality Biologics
•
InnoBiologics-B plans to list on the Science and Technology Innovation Board to raise funds for ADC drug development.Med Valley•Apr 14, 2026•Duality Biologics
•
Synnovation Announces Clinical Collaboration with DualityBio for SNV1521 CombinationBusiness Wire•Oct 14, 2025•Duality Biologics, Synnovation Therapeutics
•
BioNTech Stock Soars on Positive Phase 3 Breast Cancer Drug DataBenzinga•Sep 05, 2025•BioNTech, Duality Biologics
•
DualityBio's HER3 ADC DB-1310 Receives FDA Fast Track DesignationPR Newswire•Jul 22, 2025•Duality Biologics
•
Preliminary Data from Clinical Trials with ADC Candidates Presented at ASCO Annual Meeting 2025PR Newswire•Jun 05, 2025•Duality Biologics
•
Duality Biotherapeutics’ $211.29 Million Hong Kong IPOGlobal Legal Chronicle•Apr 18, 2025•Kirkland & Ellis, Duality Biologics
•
DualityBio, BioNTech-backed ADC maker, plans Hong Kong IPOEndPoints News•Apr 15, 2025•Duality Biologics
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Duality Biologics
Explore our recently published companies
- Safera - Mumbai based, Unfunded company
- Nova Agents AI - United Kingdom based, Unfunded company
- SafeNexus AI - United Arab Emirates based, Unfunded company
- Mike Coates - Niles based, 1958 founded, Unfunded company
- Hansa Landhandel Lahde GmbH & Co. KG - Bremervorde based, Unfunded company
- Ishq Tak Official - India based, 2016 founded, Public company
